Abstract:Background Acute renal failure (ARF) remains a frequent clinical complication, Ischemia is the major cause of acute kidney injury (AKI), associated with high mortality and morbidity. Mesenchymal stem cells (MSCs) have multilineage differentiation potential and can be a potent therapeutic option for the cure of AKI. The aim of this study was, therefore, to evaluate the therapeutic effectiveness of bone marrow–derived mesenchymal stem cells in a rat model of ischemia/reperfusion (I/R) ARF. Materials and Methods MSCs were cultured and rats were used as a common I/R model to induce ARF by clamping both renal pedicles for 45 minutes then stem cells were transplanted. Ki-67 was used as marker for regeneration of renal tubulointerstitial injury. Results This study reports that Rat MSCs decreased cell apoptosis and increased proliferation and reduced fibrosis in common I/R model in rats. Conclusion MSCs may be useful in regeneration of renal tubulointerstitial injury. INTRODUCTION The kidney is comprised of heterogeneous cell populations that function together to perform a number of tightly controlled and complex processes. Renal ischemia\ reperfusion (I\R) injury is a common cause of acute renal failure and contributed to consider able morbidity associated with surgery and anesthesia (Chander et al., 2006). One cause of acute kidney injury (AKI) is ischemia which can occur for a number of reasons, for example with the use of the vasoconstrictive drugs or radiocontrast agents; hypotension linked to loss of blood after surgery (Asif and Bruce, 2011). Stem cells play fundamental roles in the self-renewal of adult tissues throughout life. Bone marrow–derived hematopoietic stem cells have been discovered to transdifferentiate into cells of different germ layers (Krause et al., 2001). Physiologically, mesenchymal stem cells give rise to osteocytes, chondrocytes, and adipocytes, but were recently found to differentiate into endothelial, myocardial (Nagaya et al., 2004), liver (Shu et al., 2004), renal (Morigi et al., 2004), and pulmonary epithelial cells (Ortiz et al., 2003). Based on this background, the objective of the present study was to test the therapeutic potential of mesenchymal stem cells, administered to rats following induction of ARF by ischemia/reperfusion (I/R) and showed the regeneration of renal tubulointerstitial injury that marked by the pathological change and uses of marker Ki-67. Materials and Methods: Animals were approved by the animal house, faculty of science, Zagazig University, Egypt. I/R (ARF) were induced in anesthetized (ketamine/valpam) adult male Sprague Dawley rats, weighing 200 to 250 g by clamping both renal pedicles for 45 minutes. Then animals were injected with 4 ml warmed normal saline gave intraperitoneally before abdominal closure. (Claudia et al., 2005) Cell culture and transplantation Rat mesenchymal stem cells were generated from the bone marrow of adult Sprague-Dawley rats by standard procedures (Javazon et al., 2001, Lange et al., 2003). Mesenchymal stem cells used in this study were cultured for more than 3 passages, which practically excludes hematopoietic cell contamination. After 3 days of isolation non-adherent cells were removed by two to three washes with PBS and adherent cells further cultured in complete medium. The medium was changed every 3 days until the monolayer of adherent cells reach 7080% confluence. Trypsinization was made for cell splitting by Trypsin/EDTA solution (0. 25%, lonza, USA) for passage 1 .Number of cells were evaluated by Homocytometer and cellular viability by the Trypan Blue exclusion test. Each 250-300 × 103 cells were inoculated in 75 Cm2 culture flask that were incubated at 37oC and 5% CO2. Cell cultivation was maintained up to the 3rd passage. After reflow, 2 × 106 mesenchymal stem cells in 0.5 mL of complete medium were infused into the renal vein. (Uta et al., 2007). Biochemical study: Renal function was monitored by measurement of serum creatinine according to the method of (Young., 2001) and blood urea nitrogen (BUN) according to the method of (Henry et al., 1974) Histopathology study: a) Histology The kidneys were fixed in a 10% neutral-buffered formalin solution, embedded in paraffin and 5μ thick sections were stained with Hematoxylin and Eosin for injury scoring according to a previously published guideline. (Solezk et al., 1979) b) Imunohistochemstry Other sections were stained with Ki-67 imunohistochemstry

Treatment of Ischemia/Reperfusion Injury of the Kidney with Mesenchymal Stromal Cells

[Research advances on immunoregulation and anti-inflammation function of mesenchymal stem cells and their application in treatment of renal diseases].

Mesenchymal Stem Cell Therapy Targeting Mitochondrial Dysfunction in Acute Kidney Injury

Regenerative Abilities of Mesenchymal Stem Cells Via Acting As an Ideal Vehicle for Subcellular Component Delivery in Acute Kidney Injury

Current Understanding of the Administration of Mesenchymal Stem Cells in Acute Kidney Injury to Chronic Kidney Disease Transition: a Review with a Focus on Preclinical Models

Novel Preconditioning Strategies for Enhancing the Migratory Ability of Mesenchymal Stem Cells in Acute Kidney Injury

Allogeneic Mesenchymal Stem Cells As Induction Therapy Are Safe and Feasible in Renal Allografts: Pilot Results of a Multicenter Randomized Controlled Trial

Human mesenchymal stromal cells ameliorate complement induced inflammatory cascade and improve renal functions in a rat model of ischemia-reperfusion induced acute kidney injury

Single-cell dissection of cellular and molecular features underlying mesenchymal stem cell therapy in ischemic acute kidney injury

Mesenchymal stromal cells secretome restores bioenergetic and redox homeostasis in human proximal tubule cells after ischemic injury

Induction Therapy with Mesenchymal Stromal Cells in Kidney Transplantation: a Meta-Analysis

Cellular Senescence, A Novel Therapeutic Target For Mesenchymal Stem Cells In Acute Kidney Injury

High-mobility Group Box 1 Protein Antagonizes the Immunosuppressive Capacity and Therapeutic Effect of Mesenchymal Stem Cells in Acute Kidney Injury

Current Perspectives on Role of MSC in Renal Pathophysiology

Melatonin Preconditioning is an Effective Strategy for Mesenchymal Stem Cell‐based Therapy for Kidney Disease

Biochemical Evaluation to Mesenchymal Stem Cells Therapy of Renal Tubulointerstitial Injury

Melatonin preconditioning is an effective strategy for mesenchymal stem cell-based therapy for kidney disease

Preconditioning strategies for improving the survival rate and paracrine ability of mesenchymal stem cells in acute kidney injury

Preconditioning is an Effective Strategy for Improving the Efficiency of Mesenchymal Stem Cells in Kidney Transplantation

Efficiency of endovenous versus arterial administration of mesenchymal stem cells for ischemia-reperfusion-induced renal dysfunction in rats.

Mesenchymal Stem Cell Therapy in Kidney Diseases: Potential and Challenges